Journal of Clinical Oncology, Vol 16, 579-583, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Phase II trial of fludarabine monophosphate in patients with mantle- cell lymphomas

D Decaudin, J Bosq, G Tertian, G Nedellec, A Bennaceur, AM Venuat, C Bayle, P Carde, B Bendahmane, M Hayat and JN Munck
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.

PURPOSE: The aim of this phase II trial was to assess the efficacy of fludarabine monophosphate in untreated and pretreated mantle-cell lymphomas (MCL). PATIENTS AND METHODS: Fifteen patients with MCL were included in the study. In two cases, fludarabine was the first-line therapy, the second in four cases, the third in five cases, and the fourth in four cases. The diagnosis of MCL was based on the criteria of the European Lymphoma Task Force (ELTF), with morphologic, immunologic, and cytogenetic data. Patients were treated with intravenous fludarabine 25 mg/m2/d for 5 days every 4 weeks. RESULTS: Toxicity of fludarabine was mild: World Health Organization (WHO) grade 3 and 4 granulocytopenia occurred in 15 of 56 assessable cycles (cy) (27%), there was no grade 3 or 4 thrombocytopenia, one grade 3 bacterial lung infection, and no treatment-related death. There were five partial responses (33%) but no complete response. The duration of these responses was short and ranged from 4 to 8 months. CONCLUSION: These results suggest that fludarabine can be moderately effective in the treatment of MCL. Fludarabine appears to be far less effective than in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL). Therefore, fludarabine should be evaluated in association with other chemotherapeutic agents in MCL.

This article has been cited by other articles:

				T. Watanabe, N. Homma, N. Ogata, H. Saito, T. Kanefuji, K. Hasegawa, K. Soga, K. Shibasaki, T. Endo, and Y. Ajioka Complete response in a patient with colonic mantle cell lymphoma with multiple lymphomatous polyposis treated with combination chemotherapy using anti-CD20 antibody and cladribine Gut, March 1, 2007; 56(3): 449 - 450. [Full Text] [PDF]

				R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al. Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma J. Clin. Oncol., October 20, 2006; 24(30): 4867 - 4874. [Abstract] [Full Text] [PDF]

				Y. Ogawa, T. Hotta, K. Tobinai, T. Watanabe, Y. Sasaki, H. Minami, Y. Morishima, M. Ogura, and T. Seriu Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma Ann. Onc., February 1, 2006; 17(2): 330 - 333. [Abstract] [Full Text] [PDF]

				K. Tobinai, T. Watanabe, M. Ogura, Y. Morishima, Y. Ogawa, K.-i. Ishizawa, H. Minami, A. Utsunomiya, M. Taniwaki, T. Terauchi, et al. Phase II Study of Oral Fludarabine Phosphate in Relapsed Indolent B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., January 1, 2006; 24(1): 174 - 180. [Abstract] [Full Text] [PDF]

				T. E. Witzig Current Treatment Approaches for Mantle-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6409 - 6414. [Abstract] [Full Text] [PDF]

				T. E. Witzig, S. M. Geyer, I. Ghobrial, D. J. Inwards, R. Fonseca, P. Kurtin, S. M. Ansell, R. Luyun, P. J. Flynn, R. F. Morton, et al. Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma J. Clin. Oncol., August 10, 2005; 23(23): 5347 - 5356. [Abstract] [Full Text] [PDF]

				Y. Yatabe, R. Suzuki, K. Tobinai, Y. Matsuno, R. Ichinohasama, M. Okamoto, M. Yamaguchi, J.-i. Tamaru, N. Uike, Y. Hashimoto, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma Blood, April 1, 2000; 95(7): 2253 - 2261. [Abstract] [Full Text] [PDF]

				P. L. Zinzani, M. Magagnoli, L. Moretti, A. De Renzo, R. Battista, A. Zaccaria, L. Guardigni, P. Mazza, R. Marra, F. Ronconi, et al. Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma J. Clin. Oncol., February 14, 2000; 18(4): 773 - 773. [Abstract] [Full Text] [PDF]

				J. M. Foran, A. Z.S. Rohatiner, B. Coiffier, T. Barbui, S. A. Johnson, W. Hiddemann, J. A. Radford, A. J. Norton, S. M. Tollerfield, M. P. Wilson, et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstrom's Macroglobulinemia, and Mantle-Cell Lymphoma J. Clin. Oncol., February 1, 1999; 17(2): 546 - 546. [Abstract] [Full Text] [PDF]